Last updated on November 2019

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies


Brief description of study

The purpose of this study is to allow continued use of pasireotide in patients who are on pasireotide treatment in a Novartis-sponsored study and are benefiting from the treatment as judged by the investigator.

Detailed Study Description

This is a multi-center, open label, phase IV study to provide continued supply of pasireotide to patients being treated in a current Novartis-sponsored study and who are benefiting from treatment with pasireotide alone or in combination with another treatment for Cushing's Disease and Acromegaly . Eligible patients are to be consented and can then continue treatment with pasireotide alone or in combination with another treatment for Cushing's Disease and Acromegaly in this protocol. All patients at their scheduled visits will have drug dispensing information and reported adverse events and serious adverse events collected.

A patient will reach the end of study when pasireotide treatment is permanently discontinued and the end of treatment visit has been performed. All patients must be followed up for safety evaluations for 3 months following the last dose of pasireotide LAR treatment and for 1 month following the last dose of pasireotide s.c. treatment.

The study is expected to remain open for approximately 10 years or until such time that enrolled patients no longer need treatment with pasireotide or are able to obtain commercial supply according to local regulations for their medical condition.

Clinical Study Identifier: NCT01794793

Find a site near you

Start Over

Novartis Investigative Site

Le Kremlin Bicetre, France
  Connect »

Novartis Investigative Site

Marseille cedex 05, France
  Connect »

Novartis Investigative Site

Pierre Benite Cedex, France
  Connect »

Novartis Investigative Site

Seoul, Korea, Republic of
  Connect »

Novartis Investigative Site

Wilayah Persekutuan, Malaysia
  Connect »

Novartis Investigative Site

Barnaul, Russian Federation
  Connect »

Novartis Investigative Site

Moscow, Russian Federation
  Connect »

Novartis Investigative Site

Saint Petersburg, Russian Federation
  Connect »

Novartis Investigative Site

Tyumen, Russian Federation
  Connect »